Dogecoin (CRYPTO: DOGE) is trading lower Tuesday after cooling off a bit from its run over the past week. The crypto is falling back toward a potential support area. Dogecoin continues to be the most popular meme crypto in the market.
Dogecoin was down 8.73% at $0.29 at time of writing.
EXCLUSIVE: Bodybuilder Nick Balazs Does Heavy Lifting For Dogecoin
Dogecoin Daily Chart Analysis
Dogecoin has been forming a cup pattern higher toward resistance. The crypto made a decent run last week and is now cooling off and moving back toward the support from the cup pattern. The crypto trades above both the 50-day moving average (green), and 200-day moving average (blue) indicating recent sentiment in the crypto has been bullish. Each of these moving averages could hold as an area of support in the future. The $0.45 level acted as resistance in the past and may again if the crypto can reach this area. Dogecoin has been holding above the cup pattern, and this cup may continue to hold as support. The Relative Strength Index (RSI) saw a slight push lower and now sits at 54. This means that even though some sellers entered into the crypto lately, Dogecoin still has more buyers than sellers overall.
Hot Heal Care Stocks To Invest In Right Now: Cleveland BioLabs, Inc.(CBLI)
Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
